ArticleAmerican journal of translational research2015
Cisplatin induced sensory neuropathy is prevented by vascular endothelial growth factor-A.
Article in American journal of translational research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Trial
- Early-life cisplatin exposure induces neuroinflammation and chemotherapy-induced neuropathic pain.Disease models & mechanisms · 2024Article
- The Role of Vascular-Immune Interactions in Modulating Chemotherapy Induced Neuropathic Pain.Frontiers in pharmacology · 2022Article
- Modeling chemotherapy induced peripheral neuropathy (CIPN) in vitro: Prospects and limitations.Experimental neurology · 2020Review
- Exploring the Possible Mechanism and Drug Targets of Huang-Qi-Gui-Zhi-Wu-Wu Decoction for the Treatment of Chemotherapy-Induced Peripheral Neuropathy on Network Pharmacology.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Immortalized Dorsal Root Ganglion Neuron Cell Lines.Frontiers in cellular neuroscience · 2020Review
- Cancer Chemotherapy in Early Life Significantly Alters the Maturation of Pain Processing.Neuroscience · 2018Article
- Mitigation of cisplatin-induced peripheral neuropathy by canagliflozin in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2018Article
- Diabetes-induced microvascular complications at the level of the spinal cord: a contributing factor in diabetic neuropathic pain.The Journal of physiology · 2018Article
- Depletion of Mitofusin-2 Causes Mitochondrial Damage in Cisplatin-Induced Neuropathy.Molecular neurobiology · 2018Article
- Breast cancer induced nociceptor aberrant growth and collateral sensory axonal branching.Oncotarget · 2017Article
- Role of VEGF-A in chronic pain.Oncotarget · 2017Article
- Automated PGP9.5 immunofluorescence staining: a valuable tool in the assessment of small fiber neuropathy?BMC research notes · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increased patient survival is a mark of modern anti-cancer therapy success. Unfortunately treatment side-effects such as neurotoxicity are a major long term concern. Sensory neuropathy is one of the common toxicities that can arise during platinum based chemotherapy. In many cases the current poor understanding of the neurological degeneration and lack of suitable analgesia has led to high incidences of patient drop out of treatment. VEGF-A is a prominent neuroprotective agent thus it was hypothesised to prevent cisplatin induced neuropathy. Systemic cisplatin treatment (lasting 3 weeks biweekly) resulted in mechanical allodynia and heat hyperalgesia in mice when compared to vehicle control. PGP9.5 sensory nerve fibre innervation was reduced in the plantar skin in the cisplatin treated group versus vehicle control mice. The cisplatin induced sensory neurodegeneration was associated with increased cleaved caspase 3 expression as well as a reduction in Activating Transcription Factor 3 and pan VEGF-A expression in sensory neurons. VEGF-A165b expression was unaltered between vehicle and cisplatin treatment. rhVEGF-A165a and rhVEGF-A165b both prevented cisplatin induced sensory neurodegeneration. Cisplatin exposure blunts the regenerative properties of sensory neurons thus leading to sensory neuropathy. However, here it is identified that administration of VEGF-A isoform subtypes induce regeneration and prevent cell death and are therefore a possible adjunct therapy for chemotherapy induced neuropathy.
Indexed as
Identifiers
26279748PMC4532737W1165297956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.